{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:27:21Z","timestamp":1775611641713,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clinthera.2015.12.006","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T19:41:17Z","timestamp":1452195677000},"page":"372-386.e6","source":"Crossref","is-referenced-by-count":20,"title":["Effects on All-cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"38","author":[{"given":"Juan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingguo","family":"LV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanwei","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.12.006_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2015.12.006_bib2","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.12.006_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/dom.12280","article-title":"Mortality risk with sulphonylureas compared to metformin","volume":"16","author":"Holden","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2009.01125.x","article-title":"Insulin use and increased risk of mortality in type 2 diabetes: a cohort study","volume":"12","author":"Gamble","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survivial as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.12.006_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/dc10-1318","article-title":"A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study","volume":"34","author":"Colayco","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.006_bib8","doi-asserted-by":"crossref","first-page":"f2267","DOI":"10.1136\/bmj.f2267","article-title":"Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study","volume":"346","author":"Eurich","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.12.006_bib9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s00125-011-2084-x","volume":"54","author":"Mellbin","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2015.12.006_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib11","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. handbook.cochrane.org. Accessed March 20, 2011."},{"key":"10.1016\/j.clinthera.2015.12.006_bib12","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u2013853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.1016\/j.clinthera.2015.12.006_bib13","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854\u2013865","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"10.1016\/j.clinthera.2015.12.006_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1503\/cmaj.060049","article-title":"Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?","volume":"174","author":"Hiralal","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2015.12.006_bib15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2015.12.006_bib17","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2015.12.006_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1464-5491.2011.03441.x","article-title":"Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial","volume":"29","author":"Webb","year":"2012","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.12.006_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1447-0594.2011.00808.x","article-title":"Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial--study design, baseline characteristics and effects of intervention","volume":"12","author":"Araki","year":"2012","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.clinthera.2015.12.006_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/17446651.4.2.111","article-title":"Routine blood pressure lowering and intensive glucose control in patients with type 2 diabetes: the ADVANCE trial","volume":"4","author":"Joshi","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.12.006_bib24","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll of Cardiol"},{"key":"10.1016\/j.clinthera.2015.12.006_bib25","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2015.12.006_bib26","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.2337\/dc09-S339","article-title":"A summary of the ADVANCE Trial","volume":"32","author":"Heller","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.006_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.12281211","article-title":"Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study","volume":"9","author":"August","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.12.006_bib28","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/eurheartj\/eht332","article-title":"Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial","volume":"34","author":"Mellbin","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.12.006_bib29","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.2337\/dc12-2265","article-title":"Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"36","author":"Althouse","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.006_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.12.006_bib32","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.2337\/dc13-0012","article-title":"Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort","volume":"36","author":"Pop-Busui","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.006_bib33","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1210\/jc.2009-1974","article-title":"Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)","volume":"95","author":"Charbonnel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1753-0407.2010.00082.x","article-title":"PROactive Study Investigators. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)","volume":"2","author":"Erdmann","year":"2010","journal-title":"J Diabetes"},{"issue":"5 Pt 1","key":"10.1016\/j.clinthera.2015.12.006_bib35","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0167-0115(99)90004-2","article-title":"Therapy of type 2 diabetes, cardiovascular death, and the UGDP","volume":"138","author":"Feinglos","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2015.12.006_bib36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurheartj\/ehi199","article-title":"Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity","volume":"26","author":"Malmberg","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.12.006_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1463-1326.2008.00964.x","article-title":"DIGAMI 2 Investigators. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study","volume":"11","author":"Aas","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.12.006_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehm518","article-title":"DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial","volume":"29","author":"Mellbin","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.12.006_bib39","doi-asserted-by":"crossref","unstructured":"U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease U.K.Prospective Diabetes Study Group. Diabetes. 1995;44:1249\u20131258","DOI":"10.2337\/diab.44.11.1249"},{"issue":"1 Pt 2","key":"10.1016\/j.clinthera.2015.12.006_bib40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00011","article-title":"United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus","volume":"124","author":"Turner","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.12.006_bib41","first-page":"4","article-title":"Study on the intensive treatment for the new type-2 diabetes","volume":"26","author":"Ma","year":"2006","journal-title":"Harbin Med J"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.12.006_bib42","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0168-8227(09)70011-7","article-title":"Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metaanalysis of five trials","volume":"86","author":"Tkac","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2015.12.006_bib43","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.12.006_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815013223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815013223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T04:59:34Z","timestamp":1537073974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815013223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0149291815013223"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.12.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}